| Advice You |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Business > Capture Clients' Attention - Sharing Success - and the Death of Prospecting! |
|
Advice You - Capture Clients' Attention - Sharing Success - and the Death of Prospecting!
We live in a world where we are bombarded with four thousand marketing messages each day, where many struggle to keep on to According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product p of the “spam-stuffed inbox”, where every market has more sellers than buyers, where a whole new set of rapid-relationship ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in skills are called for. While some bemoan the passing of a slower-paced world, the “attention-deficit economy” is t lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. e land of opportunity for others. So how do you capture the attention of prospective customers? Networking and the here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe death of prospecting
“We are only seven steps away from anyone in the world” goes the networking mantra, so armed d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro with a tasteful business-card all we have to do is get out there, smile and be nice. Doubtless, there is some truth in all ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc of this. My own business has benefited enormously from networking. But we must ask ourselves how long will networking be easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi effective in the attention-deficit economy? If we are only seven steps away from anyone in the world, mightn’t that al nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically so spell a lot of wasted time? Ultimately, prospecting of all types will die in the attention-deficit economy.
Changing th and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ way we do our prospecting is therefore just a temporary answer. In the end, we are all so busy, we simply don’t have the t ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi ime to entertain the prospectors – no matter how alluring their wares. Successful alliances Buyers - not ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a sellers, will initiate the serious dialogue of the future. The sooner we learn to cultivate a perennial practice – a reputa dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod ion that will attract buyers - the better. We can then eliminate the time, the cost and the frustration of prospecti cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin ng entirely from a service business: and instead pursue strategies that make us outstanding. It is essential to be o tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen utstanding in the attention-deficit economy: “nice” is not enough. Who are your clients already speaking to? How can you p t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel sition yourself to catch the attention – not just of those who need your products or services, but more importantly of thos ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust e already on the attention radar-screen of those ideal clients? What (and who) would you have to be to capture the attentio y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products n of those advisors who already have the attention of your clients? These are crucial questions I have asked my clients and . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de guided them through implementation to capture that attention we all need for prosperity. (The above article is submitted o elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip n the basis that the following attribution is printed with it, using the exact wording below.)
© John Niland, November 200 tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Why I Am NOT Surprised When I Hear People Making 50 Percent Profit On a Trade - Overnight Intuition – The Gut Brain for Business Success
|